Tel J - Search Results

1

Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.

Anguille S, Lion E, Tel J, de Vries IJ, Couderé K, Fromm PD, Van Tendeloo VF, Smits EL, Berneman ZN. Anguille S, et al. Among authors: tel j. PLoS One. 2012;7(12):e51851. doi: 10.1371/journal.pone.0051851. Epub 2012 Dec 28. PLoS One. 2012. PMID: 23284789 Free PMC article.

2

CD56 marks human dendritic cell subsets with cytotoxic potential.

Roothans D, Smits E, Lion E, Tel J, Anguille S. Roothans D, et al. Among authors: tel j. Oncoimmunology. 2013 Feb 1;2(2):e23037. doi: 10.4161/onci.23037. Oncoimmunology. 2013. PMID: 23524451 Free PMC article.

3

Tumoricidal activity of human dendritic cells.

Tel J, Anguille S, Waterborg CE, Smits EL, Figdor CG, de Vries IJ. Tel J, et al. Trends Immunol. 2014 Jan;35(1):38-46. doi: 10.1016/j.it.2013.10.007. Epub 2013 Nov 18. Trends Immunol. 2014. PMID: 24262387 Free PMC article. Review.

4

Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities.

Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Tel J, et al. Blood. 2012 Nov 8;120(19):3936-44. doi: 10.1182/blood-2012-06-435941. Epub 2012 Sep 10. Blood. 2012. PMID: 22966165 Free article.

5

The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.

Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. Schreibelt G, et al. Among authors: tel j. Blood. 2012 Mar 8;119(10):2284-92. doi: 10.1182/blood-2011-08-373944. Epub 2012 Jan 10. Blood. 2012. PMID: 22234694 Free article.

6

Harnessing human plasmacytoid dendritic cells as professional APCs.

Tel J, van der Leun AM, Figdor CG, Torensma R, de Vries IJ. Tel J, et al. Cancer Immunol Immunother. 2012 Aug;61(8):1279-88. doi: 10.1007/s00262-012-1210-z. Cancer Immunol Immunother. 2012. PMID: 22294456 Free PMC article. Review.

7

Potential applications for plasmacytoid dendritic cells in cancer immunotherapy.

Tel J, de Vries IJ. Tel J, et al. Immunotherapy. 2012 Oct;4(10):979-82. doi: 10.2217/imt.12.115. Immunotherapy. 2012. PMID: 23148748 Review. No abstract available.

8

Dendritic Cells as Vaccines: Key Regulators of Tolerance and Immunity.

Tel J, Benitez-Ribas D, Janssen EM, Smits EL, Jacobs JF. Tel J, et al. Mediators Inflamm. 2016;2016:5789725. doi: 10.1155/2016/5789725. Epub 2016 May 31. Mediators Inflamm. 2016. PMID: 27340343 Free PMC article. No abstract available.

9

Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, Figdor CG. Tel J, et al. J Immunol. 2010 Apr 15;184(8):4276-83. doi: 10.4049/jimmunol.0903286. Epub 2010 Mar 19. J Immunol. 2010. PMID: 20304825

10

DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells.

Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ, Figdor CG, Tacken PJ, de Vries IJ. Tel J, et al. Eur J Immunol. 2011 Apr;41(4):1014-23. doi: 10.1002/eji.201040790. Epub 2011 Mar 17. Eur J Immunol. 2011. PMID: 21413003 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters